Live
- Army's swift action prevented Kolkata fire from spreading: Defence Ministry
- State Police tried to murder Ravi- Union minister
- FDI flow into India from Gulf countries surges to $24.54 bn in 12 years
- BBL: McSweeney hits fiery 78 to guide Heat to thrilling win after Australia snub
- 'Exceptional case..': Delhi HC orders revision of CLAT-2025 results
- South Korea reports new avian influenza case at regional farm
- US egg prices soar to yearly high amid bird flu, holiday demand
- Ayushman Bharat proving to be boon for people in Gujarat's Kheda
- SEBI takes strict action in front running case, bars 9 entities, seizes over Rs 21 crore (Lead)
- Grand 30th Alumni Reunion at Vattam Jawahar Navodaya Vidyalaya
Zydus Cadila receives tentative approval from USFDA for Pimavanserin Capsules
Zydus Cadila receives tentative approval from USFDA for Pimavanserin Capsules
Zydus Cadila’s U.S. subsidiary Zydus Pharmaceuticals (USA) Inc. on Friday, December 31, 2021, announced that it has received tentative approval from the USFDA to market Pimavanserin Capsules in the strength of 34 mg (USRLD: Nuplazid® Capsules).
Zydus Cadila's U.S. subsidiary Zydus Pharmaceuticals (USA) Inc. on Friday, December 31, 2021, announced that it has received tentative approval from the USFDA to market Pimavanserin Capsules in the strength of 34 mg (USRLD: Nuplazid® Capsules).
Pimavanserin is an atypical antipsychotic and is indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The drug will be manufactured at the group's formulation manufacturing facility at SEZ Ahmedabad. The group now has 325 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 23000 people worldwide and is dedicated to creating healthier communities globally.
Shares of Cadila Healthcare Ltd closed at Rs 483.35 per share on Friday, 0.84 per cent higher against the previous close of Rs 479.30 per share at BSE.
